Leishmaniasis in humans: drug or vaccine therapy?

References

• CabezasYLegentilLRobert-GangneuxFLeishmania cell wall as a potent target for antiparasitic drugs. A focus on the glycoconjugatesOrg Biomol Chem201513318393840426130402
   PubMed Web of Science ®Google Scholar
• de FreitasEOLeorattiFMFreire-de-LimaCGMorrotAFeijóDFThe contribution of immune evasive mechanisms to parasite persistence in visceral leishmaniasisFront Immunol2016715327148272
   PubMed Web of Science ®Google Scholar
• de VriesHJReedijkSHSchalligHDCutaneous leishmaniasis: recent developments in diagnosis and managementAm J Clin Dermatol20151629910925687688
   PubMed Web of Science ®Google Scholar
• PearsonRDSousaAQClinical spectrum of leishmaniasisClin Infect Dis1996111
   PubMed Web of Science ®Google Scholar
• SavoiaDRecent updates and perspectives on leishmaniasisJ Infect Dev Ctries20159658859626142667
   PubMed Web of Science ®Google Scholar
• MollHBerberichCDendritic cell-based vaccination strategies: induction of protective immunity against leishmaniasisImmunobiology2001204565966611846231
   PubMed Web of Science ®Google Scholar
• PetersNCEgenJGSecundinoNIn vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand fliesScience2008321589197097418703742
   PubMed Web of Science ®Google Scholar
• AmulicBCazaletCHayesGLMetzlerKDZychlinskyANeutrophil function: from mechanisms to diseaseAnnu Rev Immunol20123045948922224774
   PubMed Web of Science ®Google Scholar
• AntonelliLRDutraWOAlmeidaRPBacellarOCarvalhoEMGollobKJActivated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasisImmunol Lett2005101222623016083969
   PubMed Web of Science ®Google Scholar
• BacellarOLessaHSchrieferAUp-regulation of Th1-type responses in mucosal leishmaniasis patientsInfect Immun200270126734674012438348
   PubMed Web of Science ®Google Scholar
• ConceiçãoJDavisRCarneiroPPCharacterization of neutrophil function in human cutaneous leishmaniasis caused by leishmania braziliensisPLoS Negl Trop Dis2016105e000471527167379
   PubMed Web of Science ®Google Scholar
• MüllerKvan ZandbergenGHansenBChemokines, natural killer cells and granulocytes in the early course of Leishmania major infection in miceMed Microbiol Immunol20011901–2737611770115
   PubMed Web of Science ®Google Scholar
• Ribeiro-de-JesusAAlmeidaRPLessaHBacellarOCarvalhoEMCytokine profile and pathology in human leishmaniasisBraz J Med Biol Res19983111431489686192
   PubMed Web of Science ®Google Scholar
• Freitas-JuniorLHChatelainEKimHASiqueira-NetoJLVisceral leishmaniasis treatment: what do we have, what do we need and how to deliver it?Int J Parasitol Drug Resist201221119
   PubMed Web of Science ®Google Scholar
• RajasekaranRChenYPPotential therapeutic targets and the role of technology in developing novel antileishmanial drugsDrug Discov Today201520895896825936844
   PubMed Web of Science ®Google Scholar
• DuthieMSFavilaMHofmeyerKAStrategic evaluation of vaccine candidate antigens for the prevention of visceral leishmaniasisVaccine201634252779278627142329
   PubMed Web of Science ®Google Scholar
• SundarSDrug resistance in Indian visceral leishmaniasisTrop Med Int Health200161184985411703838
   PubMed Web of Science ®Google Scholar
• CroftSLCoombsGHLeishmaniasis–current chemotherapy and recent advances in the search for novel drugsTrends Parasitol2003191150250814580961
   PubMed Web of Science ®Google Scholar
• DorloTPRijalSOstynBFailure of miltefosine in visceral leishmaniasis is associated with low drug exposureJ Infect Dis2014210114615324443541
   PubMed Web of Science ®Google Scholar
• JainKJainNKVaccines for visceral leishmaniasis: a reviewJ Immunol Methods201542211225858230
   PubMed Web of Science ®Google Scholar
• MinodierPParolaPCutaneous leishmaniasis treatmentTravel Med Infect Dis20075315015817448941
   PubMedGoogle Scholar
• MoskowitzPFKurbanAKTreatment of cutaneous leishmaniasis: retrospectives and advances for the 21st centuryClin Dermatol199917330531510384870
   PubMed Web of Science ®Google Scholar
• ReithingerRDujardinJCLouzirHPirmezCAlexanderBBrookerSCutaneous leishmaniasisLancet Infect Dis20077958159617714672
   PubMed Web of Science ®Google Scholar
• PalumboETreatment strategies for mucocutaneous leishmaniasisJ Glob Infect Dis20102214715020606970
   PubMedGoogle Scholar
• AsteNPauMFerreliCBiggioPIntralesional treatment of cutaneous leishmaniasis with meglumine antimoniateBr J Dermatol199813823703719602904
   PubMed Web of Science ®Google Scholar
• BlumJDesjeuxPSchwartzEBeckBHatzCTreatment of cutaneous leishmaniasis among travellersJ Antimicrob Chemother200453215816614729756
   PubMed Web of Science ®Google Scholar
• ManfrediMIulianoSBizzarriBFugazzaAGismondiPCutaneous leishmaniasis with long duration and bleeding ulcerClin Microbiol20165229
   Google Scholar
• CoelhoDRDe-OliveiraAParenteTIn vivo and in vitro effects of pentavalent antimony on mouse liver cytochrome P450sHum Exp Toxicol Epub201634
   Web of Science ®Google Scholar
• HermanJDGallaleeJVBestJMSodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid β-oxidation in Leishmania mexicana amastigotesBiochem Pharmacol19873621972013028425
   PubMed Web of Science ®Google Scholar
• CroftSLSundarSFairlambAHDrug resistance in leishmaniasisClin Microbiol Rev200619111112616418526
   PubMed Web of Science ®Google Scholar
• de Souza MoreiraDFerreiraRFMurtaSMMolecular characterization and functional analysis of pteridine reductase in wild-type and antimony-resistant Leishmania linesExp Parasitol2016160606626689884
   PubMed Web of Science ®Google Scholar
• NareBGarrawayLAVickersTJBeverleySMPTR1-dependent synthesis of tetrahydrobiopterin contributes to oxidant susceptibility in the trypanosomatid protozoan parasite Leishmania majorCurr Genet200955328729919396443
   PubMed Web of Science ®Google Scholar
• de MouraTRSantosMLBrazJMCross-resistance of Leishmania infantum isolates to nitric oxide from patients refractory to antimony treatment, and greater tolerance to antileishmanial responses by macrophagesParasitol Res2016115271372126481489
   PubMed Web of Science ®Google Scholar
• Adler-MooreJPProffittRTDevelopment, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin BJ Liposome Res199333429450
   Google Scholar
• Al-AbdelyHMGraybillJRBocanegraREfficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasisAntimicrob Agents Chemother19984210254225489756753
   PubMed Web of Science ®Google Scholar
• EspuelasMSLegrandPCampaneroMAPolymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic miceJ Antimicrob Chemother200352341942712888593
   PubMed Web of Science ®Google Scholar
• GuoLSWorkingPKComplexes of amphotericin B and cholesteryl sulfateJ Liposome Res199333473490
   Google Scholar
• LarabiMGulikADedieuJPLegrandPBarrattGCheronMNew lipid formulation of amphotericin B: spectral and microscopic analysisBiochim Biophys Acta20041664217218115328049
   PubMed Web of Science ®Google Scholar
• Lopez-BeresteinGHopferRLMehtaRMehtaKHershEMJulianoRLLiposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic miceJ Infect Dis198415022782836470530
   PubMed Web of Science ®Google Scholar
• StoneNRBicanicTSalimRHopeWLiposomal amphotericin B (AmBisome®): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directionsDrugs201676448550026818726
   PubMed Web of Science ®Google Scholar
• Adler-MooreJProffittRTAmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experienceJ Antimicrob Chemother200249suppl 1213011801577
   PubMed Web of Science ®Google Scholar
• FujiiGChangJEColeyTSteereBThe formation of amphotericin B ion channels in lipid bilayersBiochemistry19973616495949689125518
   PubMed Web of Science ®Google Scholar
• PapahadjopoulosDJacobsonKNirSIsacIPhase transitions in phospholipid vesicles fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterolBiochim Biophys Acta197331133303484729825
   PubMed Web of Science ®Google Scholar
• WasanEKGershkovichPZhaoJA novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine modelPLoS Negl Trop Dis2010412e91321151883
   PubMed Web of Science ®Google Scholar
• MistroSRodriguesMRosaLCamargoMBadaróRLiposomal amphotericin B drug access for the treatment of leishmaniasis in BrazilTrop Med Int Health201621669269327037644
   PubMed Web of Science ®Google Scholar
• BellmannRClinical pharmacokinetics of systemically administered antimycoticsCurr Clin Pharmacol200721375818690854
   PubMedGoogle Scholar
• BellmannREggerPWiedermannCJDifferences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalenceClin Infect Dis200336111500150112766850
   PubMed Web of Science ®Google Scholar
• FeltonTTrokePFHopeWWTissue penetration of antifungal agentsClin Microbiol Rev2014271688824396137
   PubMed Web of Science ®Google Scholar
• GrollAHLymanCAPetraitisVCompartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulationsAntimicrob Agents Chemother200650103418342317005824
   PubMed Web of Science ®Google Scholar
• WalshTJFinbergRWArndtCLiposomal amphotericin B for empirical therapy in patients with persistent fever and neutropeniaN Engl J Med19993401076477110072411
   PubMed Web of Science ®Google Scholar
• CroftSLMonitoring drug resistance in leishmaniasisTrop Med Int Health200161189990511703844
   PubMed Web of Science ®Google Scholar
• MistroSMaciel IdeMde MenezesRGMaiaZPSchooleyRTBadaróRDoes lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysisClin Infect Dis201254121774177722491505
   PubMed Web of Science ®Google Scholar
• BalasegaramMRitmeijerKLimaMALiposomal amphotericin B as a treatment for human leishmaniasisExpert Opin Emerg Drugs201217449351023167833
   PubMed Web of Science ®Google Scholar
• MeheusFBalasegaramMOlliaroPCost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinentPLoS Negl Trop Dis201049e81820838649
   PubMed Web of Science ®Google Scholar
• OlliaroPDarleySLaxminarayanRSundarSCost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, IndiaTrop Med Int Health200914891892519563434
   PubMed Web of Science ®Google Scholar
• SolomonMBaumSBarzilaiAScopeATrauHSchwartzELiposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensisJ Am Acad Dermatol200756461261617276541
   PubMed Web of Science ®Google Scholar
• EchevarríaIBarturenCRenedoMJTrocónizIFDios-ViéitezMCComparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in ratsAntimicrob Agents Chemother200044489890410722488
   PubMed Web of Science ®Google Scholar
• FieldingRMSmithPCWangLHPorterJGuoLSComparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to ratsAntimicrob Agents Chemother1991356120812131929263
   PubMed Web of Science ®Google Scholar
• KhanMAOwaisMToxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine modelJ Antimicrob Chemother200658112513216709592
   PubMed Web of Science ®Google Scholar
• WasanKMMortonRERosenblumMGLopez-BeresteinGDecreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: Role of lipid transfer proteinJ Pharm Sci1994837100610107965656
   PubMed Web of Science ®Google Scholar
• PatereSNPathakPOKumar ShuklaASurface-modified liposomal formulation of amphotericin B: in vitro evaluation of potential against visceral leishmaniasisAAPS Pharm Sci Tech2017183710720
   PubMed Web of Science ®Google Scholar
• SinghPKSahPMeherJGMacrophage-targeted chitosan anchored PLGA nanoparticles bearing doxorubicin and amphotericin B against visceral leishmaniasisRSC Adv20166757170571718
   Web of Science ®Google Scholar
• LarabiMLegrandPBarrattGAn original lipid complex system for amphotericin B. Liposome technology: entrapment of drugs and other materials into liposomesCurr Opin Infect Dis2016293
   Google Scholar
• SundarSSinghARecent developments and future prospects in the treatment of visceral leishmaniasisTher Adv Infect Dis20163349810927536354
   PubMedGoogle Scholar
• BrothertonMCBourassaSLégaréDPoirierGGDroitAOuelletteMQuantitative proteomic analysis of amphotericin B resistance in Leishmania infantumInt J Parasitol Drugs Drug Resist20144212613225057462
   PubMed Web of Science ®Google Scholar
• CohenBEResistance responses to amphotericin B: the role of signaling via aqueous pores formationAntimicrob Agents Chemother20166095122512927381391
   PubMed Web of Science ®Google Scholar
• McGonigleSDaltonJPJamesERPeroxidoxins: a new antioxidant familyParasitol Today199814413914517040731
   PubMedGoogle Scholar
• PurkaitBKumarANandiNMechanism of amphotericin B resistance in clinical isolates of Leishmania donovaniAntimicrob Agents Chemother20125621031104122123699
   PubMed Web of Science ®Google Scholar
• CroftSLSeifertKDuchêneMAntiprotozoal activities of phospholipid analoguesMol Biochem Parasitol2003126216517212615315
   PubMed Web of Science ®Google Scholar
• DorloTPBalasegaramMBeijnenJHde VriesPJMiltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisJ Antimicrob Chemother201267112576259722833634
   PubMed Web of Science ®Google Scholar
• BreiserAKimDJFleerEADistribution and metabolism of hexadecylphosphocholine in miceLipids198722119259263444386
   PubMed Web of Science ®Google Scholar
• PersonCApplication for Inclusion of Emtricitabine On WHO Model List of Essential MedicinesGilead Sciences, IncFoster City, California, USA102004
   Google Scholar
• RuiterGAZerpSFBartelinkHvan BlitterswijkWJVerheijMAnti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase–Akt/PKB survival pathwayAnticancer Drugs200314216717312569304
   PubMed Web of Science ®Google Scholar
• CoelhoACMiltefosine susceptibility and resistance in leishmania: from the laboratory to the fieldJ Trop Dis20164203
   Google Scholar
• LaffitteMCLeprohonPLégaréDOuelletteMDeep-sequencing revealing mutation dynamics in the miltefosine transporter gene in Leishmania infantum selected for miltefosine resistanceParasitol Res2016115103699370327457482
   PubMed Web of Science ®Google Scholar
• MondalDHasnainMGHossainMSStudy on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniasis: an open clinical trial and case–control study protocolBMJ Open201665e010050
   PubMed Web of Science ®Google Scholar
• Pérez-VictoriaFJGamarroFOuelletteMCastanysSFunctional cloning of the miltefosine transporter A novel P-type phospholipid translocase from leishmania involved in drug resistanceJ Biol Chem200327850499654997114514670
   PubMed Web of Science ®Google Scholar
• MaranNGomesPSFreire-de-LimaLFreitasEOFreire-de-LimaCGMorrotAHost resistance to visceral leishmaniasis: prevalence and preventionExpert Rev Anti Infect Ther201614443544226934623
   PubMed Web of Science ®Google Scholar
• WasunnaMNjengaSBalasegaramMEfficacy and safety of AmBisome in combination with sodium stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: phase II randomized trialPLoS Negl Trop Dis2016109e000488027627654
   PubMed Web of Science ®Google Scholar
• McMichaelAJKoffWCVaccines that stimulate T cell immunity to HIV-1: the next stepNat Immunol201415431932224646598
   PubMed Web of Science ®Google Scholar
• ChoudhuryRDasPDeTChakrabortiT115kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activityImmunobiology2013218111412622440312
   PubMed Web of Science ®Google Scholar
• GiunchettiRCReisABda Silveira-LemosDAntigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasisRes Vet Sci200885110611217950391
   PubMed Web of Science ®Google Scholar
• KhalilEAEl HassanAMZijlstraEEAutoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in SudanLancet200035692411565156911075771
   PubMed Web of Science ®Google Scholar
• ChakravartyJKumarSTrivediSA clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+ MPL-SE vaccine for use in the prevention of visceral leishmaniasisVaccine201129193531353721414377
   PubMed Web of Science ®Google Scholar
• BadaroRLoboINakataniMSuccessful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal Leishmaniasis refractory to antimony: a case reportBraz J Infect Dis20015422323211712967
   PubMedGoogle Scholar
• GenaroOde ToledoVPda CostaCAHermetoMVAfonsoLCMayrinkWVaccine for prophylaxis and immunotherapy, BrazilClin Dermatol19961455035128889328
   PubMed Web of Science ®Google Scholar
• MohebaliMKhamesipourAMobediIZareiZHashemi-FesharkiRDouble-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. IranVaccine20042229–304097410015364462
   PubMed Web of Science ®Google Scholar
• NoazinSKhamesipourAMoultonLHEfficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysisVaccine200927354747475319540273
   PubMed Web of Science ®Google Scholar
• DuthieMSReedSGThe emergence of defined subunit vaccines for the prevention of leishmaniasisCurr Trop Med Rep201413154162
   Google Scholar
• GuhaRDasSGhoshJHeterologous priming–boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovaniVaccine201331151905191523499564
   PubMed Web of Science ®Google Scholar
• GuhaRGuptaDRastogiRVaccination with leishmania hemoglobin receptor–encoding DNA protects against visceral leishmaniasisSci Transl Med20135202202ra121
   PubMed Web of Science ®Google Scholar
• TewaryPJainMSahaniMHSaxenaSMadhubalaRA heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasisJ Infect Dis2005191122130213715898000
   PubMed Web of Science ®Google Scholar
• MahdaviMMavandadnejadFYazdiMHOral administration of synthetic selenium nanoparticles induced robust Th1 cytokine pattern after HBs antigen vaccination in mouse modelJ Infect Public Health201710110210927026241
   PubMed Web of Science ®Google Scholar
• NoazinSModabberFKhamesipourAFirst generation leishmaniasis vaccines: a review of field efficacy trialsVaccine200826526759676718950671
   PubMed Web of Science ®Google Scholar
• ArmijosRXWeigelMMAvilesHMaldonadoRRacinesJField trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-upJ Infect Dis19981775135213579593024
   PubMed Web of Science ®Google Scholar
• VelezIAgudeloSHendrickxEInefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis: a randomized, controlled trialAnn Intern Med199712632322369027276
   PubMed Web of Science ®Google Scholar
• Machado-PintoJPintoJda CostaCAImmunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonialInt J Dermatol2002412737811982640
   PubMed Web of Science ®Google Scholar
• MayrinkWda CostaCAMagalhãesPAA field trial of a vaccine against American dermal leishmaniasisTrans R Soc Trop Med Hyg1979734385387555064
   PubMed Web of Science ®Google Scholar
• AntunesCMMayrinkWMagalhaesPAControlled field trials of a vaccine against new world cutaneous leishmaniasisInt J Epidemiol19861545725803546170
   PubMed Web of Science ®Google Scholar
• De LucaPMMayrinkWPintoJAA randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasisActa Trop200180325126011700183
   PubMed Web of Science ®Google Scholar
• MayrinkWSantosGCToledo VdePVaccination of C57BL/10 mice against cutaneous leishmaniasis using killed promastigotes of different strains and species of LeishmaniaRev Soc Bras Med Trop200235212513212011920
   PubMedGoogle Scholar
• VélezIDdel Pilar AgudeloSArbelaezMPSafety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trialTrans R Soc Trop Med Hyg200094669870311198661
   PubMed Web of Science ®Google Scholar
• VélezIDGilchristKArbelaezMPFailure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in ColombiaTrans R Soc Trop Med Hyg200599859359815893351
   PubMed Web of Science ®Google Scholar
• ArmijosRXWeigelMMRomeroLGarciaVSalazarJField trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-upJ Infect Dis19981775135213579593024
   PubMed Web of Science ®Google Scholar
• ArmijosRXWeigelMMRomeroLGarciaVSalazarJField trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: how long does protection last?J Infect Dis2003187121959196112792873
   PubMed Web of Science ®Google Scholar
• KhamesipourARafatiSDavoudiNMaboudiFModabberFLeishmaniasis vaccine candidates for development: a global overviewIndian J Med Res2006123342343816778321
   PubMed Web of Science ®Google Scholar
• ModabberFFirst generation leishmaniasis vaccines in clinical development: moving, but what nextCurr Opin Investig Drugs200023539
   Google Scholar
• MahmoodiMKhamesipourADowlatiYImmune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCGClin Exp Immunol2003134230330814616791
   PubMed Web of Science ®Google Scholar
• MomeniAZJalayerTEmamjomehMA randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in IranVaccine199917546647210073725
   PubMed Web of Science ®Google Scholar
• SharifiIFeKriARAflatonianMRRandomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, IranLancet199835191151540154310326536
   PubMed Web of Science ®Google Scholar
• KhalilEAElhassanAMZijlstraEESafety and immunogenicity of an autoclaved Leishmania major vaccineEast Afr Med J200077946847012862135
   PubMed Web of Science ®Google Scholar
• MusaAMKhalilEAMahgoubFALeishmaniasis Research Group/SudanImmunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatmentTrans R Soc Trop Med Hyg20081021586317963805
   PubMed Web of Science ®Google Scholar
• SattiINOsmanHYDaifallaNSImmunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteersVaccine20011915–162100210611228382
   PubMed Web of Science ®Google Scholar
• AlexanderJCoombsGHMottramJCLeishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 responseJ Immunol199816112679468019862710
   PubMed Web of Science ®Google Scholar
• CruzACoburnCMBeverleySMDouble targeted gene replacement for creating null mutantsProc Natl Acad Sci U S A19918816717071741651496
   PubMed Web of Science ®Google Scholar
• GholamiEZahedifardFRafatiSDelivery systems for Leishmania vaccine developmentExpert Rev Vaccines201615787989526905526
   PubMed Web of Science ®Google Scholar
• MuyombweAOlivierMHarviePBergeronMGOuelletteMPapadopoulouBProtection against Leishmania major challenge infection in mice vaccinated with live recombinant parasites expressing a cytotoxic geneJ Infect Dis199817711881959419187
   PubMed Web of Science ®Google Scholar
• EdrissianGHMohammadiMKananiABacterial infections in suspected cutaneous leishmaniasis lesionsBull World Health Organ19906844734772208560
   PubMed Web of Science ®Google Scholar
• RequenaJMIborraSCarriónJAlonsoCSotoMRecent advances in vaccines for leishmaniasisExpert Opin Biol Ther2004491505151715335317
   PubMed Web of Science ®Google Scholar
• SchofieldCUNDP/World Bank/WHO special programme for research and training in tropical diseases (TDR)Parasitology Today198958235238
   Google Scholar
• SouzaAEBatesPACoombsGHMottramJCNull mutants for the lmcpa cysteine proteinase gene in Leishmania mexicanaMol Biochem Parasitol19946322132208008019
   PubMed Web of Science ®Google Scholar
• AfrinFRajeshRAnamKGopinathMPalSAliNCharacterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c miceInfect Immun200270126697670612438344
   PubMed Web of Science ®Google Scholar
• SrivastavaSShankarPMishraJSinghSPossibilities and challenges for developing a successful vaccine for leishmaniasisParasit Vectors20169127727175732
   PubMed Web of Science ®Google Scholar
• PetitdidierEPagniezJPapierokGVincendeauPLemesreJLBras-GonçalvesRRecombinant forms of Leishmania amazonensis excreted/secreted promastigote surface antigen (PSA) induce protective immune responses in dogsPLoS Negl Trop Dis2016105e000461427223609
   PubMed Web of Science ®Google Scholar
• GonzaloRMdel RealGRodriguezJRA heterologous prime–boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasisVaccine20022071226123111803085
   PubMed Web of Science ®Google Scholar
• RamırezJRGilchristKRobledoSSepúlvedaJCMollHSoldatiDAttenuated Toxoplasma gondii ts-4 mutants engineered to express the Leishmania antigen KMP-11 elicit a specific immune response in BALB/c miceVaccine200120345546111672909
   PubMed Web of Science ®Google Scholar
• RamiroMJZárateJJHankeTProtection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACKVaccine20032119–202474248412744881
   PubMed Web of Science ®Google Scholar
• StreitJAReckerTJDonelsonJEWilsonMEBCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible miceExp Parasitol2000941334110631078
   PubMed Web of Science ®Google Scholar
• XuDMcsorleySJChatfieldSNDouganGLiewFYProtection against Leishmania major infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (AroA-AroD-)Immunology1995851177635511
   PubMed Web of Science ®Google Scholar
• MarcianiDJVaccine adjuvants: role and mechanisms of action in vaccine immunogenicityDrug Discov Today200382093494314554157
   PubMed Web of Science ®Google Scholar
• Borja-CabreraGPSantosFNBauerFSImmunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in BrazilVaccine200826394991499718675868
   PubMed Web of Science ®Google Scholar
• Palatnik-de-SousaCBVaccines for leishmaniasis in the fore coming 25 yearsVaccine200826141709172418295939
   PubMed Web of Science ®Google Scholar
• Campos-NetoAPorrozziRGreesonKProtection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human diseaseInfect Immun20016964103410811349082
   PubMed Web of Science ®Google Scholar
• FujiwaraRTValeAMFranca da SilvaJCImmunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasisVet Res2005365–682783816120256
   PubMed Web of Science ®Google Scholar
• GhalibHModabberFConsultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasisKinetoplastid Biol Dis20076717705861
   PubMedGoogle Scholar
• GurunathanSPrussinCSacksDLSederRAVaccine requirements for sustained cellular immunity to an intracellular parasitic infectionNat Med1998412140914159846579
   PubMed Web of Science ®Google Scholar
• NoormohammadiAHHochreinHCurtisJMBaldwinTMHandmanEParadoxical effects of IL-12 in leishmaniasis in the presence and absence of vaccinating antigenVaccine20011928–294043405211427281
   PubMed Web of Science ®Google Scholar
• PootJSpreeuwenbergKSandersonSJVaccination with a preparation based on recombinant cysteine peptidases and canine IL-12 does not protect dogs from infection with Leishmania infantumVaccine200624142460246816423430
   PubMed Web of Science ®Google Scholar
• BretonMTremblayMJOuelletteMPapadopoulouBLive nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasisInfect Immun200573106372638216177308
   PubMed Web of Science ®Google Scholar
• MizbaniATaheriTZahedifardFRecombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasisVaccine2009281536219818721
   PubMed Web of Science ®Google Scholar
• MahdaviMEbtekarMKhorram KhorshidHRAzadmaneshKHartoonianCHassanZMELISPOT analysis of a new CTL based DNA vaccine for HIV-1 using GM-CSF in DNA prime/peptide boost strategy: GM-CSF induced long-lived memory responsesImmunol Lett20111401–2142021679728
   PubMed Web of Science ®Google Scholar
• Campos-NetoAWebbJRGreesonKColerRNSkeikyYAReedSGVaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c miceInfect Immun20027062828283612010969
   PubMed Web of Science ®Google Scholar
• HartoonianCEbtekarMSoleimanjahiHEffect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccineCytokine2009461435019278866
   PubMed Web of Science ®Google Scholar
• IborraSSotoMCarriónJAlonsoCRequenaJMVaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosisVaccine20042229–303865387615364433
   PubMed Web of Science ®Google Scholar
• JamaliAMahdaviMHassanZMA novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccineInt Immunol200921321722519174474
   PubMed Web of Science ®Google Scholar
• Velashjerdi FarahaniSReza AghasadeghiMMemarnejadianAFaeziSShahosseiniZMahdaviMNaloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responsesPathog Glob Health20161102394726403975
   PubMed Web of Science ®Google Scholar
• DoroudDVatanaraAZahedifardFCationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluationsJ Pharm Pharm Sci201013332033521092706
   PubMed Web of Science ®Google Scholar
• MehnertWMäderKSolid lipid nanoparticles: production, characterization and applicationsAdv Drug Deliv Rev2001472–316519611311991
   PubMed Web of Science ®Google Scholar
• MuÈllerRHMaÈderKGohlaSSolid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the artEur J Pharm Biopharm200050116117710840199
   PubMed Web of Science ®Google Scholar
• SaljoughianNZahedifardFDoroudDCationic solid–lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in miceParasite Immunol2013351239740823710803
   PubMed Web of Science ®Google Scholar
• TafaghodiMEskandariMKhamesipourAJaafariMRAlginate microspheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN induced partial protection and enhanced immune response against murine model of leishmaniasisExp Parasitol2011129210711421767536
   PubMed Web of Science ®Google Scholar
• TafaghodiMSajadi TabasiSAPayanMAlginate microsphere as a delivery system and adjuvant for autoclaved Leishmania major and Quillaja saponin: preparation and characterizationIran J Pharm Sci2007326168
   Google Scholar
• TafaghodiMTabassiSASJaafariMRInduction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODNInt J Pharm20063191–2374316701972
   PubMed Web of Science ®Google Scholar
• MehravaranAJaafariMRJalaliSAKhamesipourATafaghodiMHojatizadeMThe role of surface charge of ISCOMATRIX nanoparticles on the type of immune response generated against Leishmaniasis in BALB/c miceNanomed J201524249260
   Google Scholar
• SaburAAsadMAliNLipid based delivery and immuno-stimulatory systems: master tools to combat leishmaniasisCell Immunol2016309556027470274
   PubMed Web of Science ®Google Scholar
• Zambrano-VillaSRosales-BorjasDCarreroJCOrtiz-OrtizLHow protozoan parasites evade the immune responseTrends Parasitol200218627227812036742
   PubMed Web of Science ®Google Scholar
• ReedSGColerRNMondalDKamhawiSValenzuelaJGLeishmania vaccine development: exploiting the host-vector-parasite interfaceExpert Rev Vaccines2016151819026595093
   PubMed Web of Science ®Google Scholar